Anne Johnson - ATAI Life Chief Officer
| ATAI Stock | USD 1.33 0.03 2.21% |
Insider
Anne Johnson is Chief Officer of ATAI Life Sciences
| Age | 55 |
| Address | Wallstrasse 16, Berlin, Germany, 10179 |
| Phone | 49 89 2153 9035 |
| Web | https://www.atai.life |
Anne Johnson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Anne Johnson against ATAI Life stock is an integral part of due diligence when investing in ATAI Life. Anne Johnson insider activity provides valuable insight into whether ATAI Life is net buyers or sellers over its current business cycle. Note, ATAI Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell ATAI Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Anne Johnson over six months ago Disposition of 200000 shares by Anne Johnson of ATAI Life subject to Rule 16b-3 | ||
Anne Johnson over a year ago ATAI Life exotic insider transaction detected |
ATAI Life Management Efficiency
The company has return on total asset (ROA) of (0.2541) % which means that it has lost $0.2541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6277) %, meaning that it created substantial loss on money invested by shareholders. ATAI Life's management efficiency ratios could be used to measure how well ATAI Life manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.14. The current Return On Capital Employed is estimated to decrease to -0.48. As of now, ATAI Life's Total Current Assets are increasing as compared to previous years. The ATAI Life's current Debt To Assets is estimated to increase to 0.06, while Total Assets are projected to decrease to under 261.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Greg Cavers | Cybin Inc | 53 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Wong JD | Mind Medicine | 54 | |
| Jeffery MD | Bio Path Holdings | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Michael Gerometta | Opthea | 59 | |
| Elizabeth Evans | Vaccinex | 51 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| MBA CFA | Vaccinex | 50 | |
| Douglas Drysdale | Cybin Inc | 54 | |
| Julie ACA | GH Research PLC | 38 | |
| Ian Leitch | Opthea | 61 | |
| Magnus Halle | GH Research PLC | 27 | |
| CPA CPA | Opthea | 63 | |
| Leah Gibson | Cybin Inc | N/A | |
| Schond Greenway | Mind Medicine | 52 | |
| Thomas Schaible | Fortress Biotech | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Yvonne McGrath | Iteos Therapeutics | 50 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.25 |
ATAI Life Sciences Leadership Team
Elected by the shareholders, the ATAI Life's board of directors comprises two types of representatives: ATAI Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ATAI. The board's role is to monitor ATAI Life's management team and ensure that shareholders' interests are well served. ATAI Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ATAI Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ryan JD, General VP | ||
| Rolando MD, Chief Officer | ||
| Stephen Bardin, Advisor | ||
| Ryan Barrett, General VP | ||
| Michael Raven, Senior Operations | ||
| Madison Crawford, Sr Accounting | ||
| Glenn Short, Senior Development | ||
| Frank Stegert, Vice Management | ||
| Christian Angermayer, Founder Board | ||
| Florian Brand, Cofounder CEO | ||
| Anne Johnson, Chief Officer | ||
| Sahil MD, Chief Officer | ||
| Kevin MD, Senior Development | ||
| Aaqil Anwar, Mang Relations |
ATAI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ATAI Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (565.05) % | ||||
| Current Valuation | 166.1 M | ||||
| Shares Outstanding | 167.8 M | ||||
| Shares Owned By Insiders | 9.98 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 10.2 M | ||||
| Price To Earning | 0.30 X | ||||
| Price To Book | 1.57 X |
Currently Active Assets on Macroaxis
When determining whether ATAI Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ATAI Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atai Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atai Life Sciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ATAI Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATAI Life. If investors know ATAI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATAI Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (0.80) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.54) | Return On Assets (0.25) |
The market value of ATAI Life Sciences is measured differently than its book value, which is the value of ATAI that is recorded on the company's balance sheet. Investors also form their own opinion of ATAI Life's value that differs from its market value or its book value, called intrinsic value, which is ATAI Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATAI Life's market value can be influenced by many factors that don't directly affect ATAI Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATAI Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATAI Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATAI Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.